OverviewZENAPAX 25MG INJ is a Schedule H drug.
ZENAPAX 25MG INJ is composed of: DACLIZUMAB (25.0 MG)
Daclizumab is a monoclonal antibody that affects the actions of the body’s immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Daclizumab is used to treat relapsing forms of multiple
UsageDACLIZUMAB is generally used to treat: Multiple Sclerosis
Frequently Asked QuestionsQ: Is it safe for children?
A: Ask your doctor
Q: Can it be taken during pregnancy?
A: Considered as Generally Safe – not enough studies to prove risk
Do not receive a "live" vaccine while using daclizumab and for at least 4 months after your last dose. Caution should be exercised in patients with any allergy, during pregnancy and breastfeeding. It may cause dizziness or blurred vision, do not drive a car or operate machinery while taking this medication. It may affect blood sugar level; monitor sugar level regularly while taking this medication.
Common Side-EffectsDACLIZUMAB : Dark Colored (brown) Urine, Fatigue (tiredness), Weakness (generalized), Loss Of Appetite, Abdomen Pain, Vomit, Eyes Yellow Eyes
Serious Side-EffectsDACLIZUMAB : Cloudy Urine With Strong Odor, Body Pain, Cough, Hoarse Voice, Head Headache, Nasal Congestion, Runny Nose, Throat Soreness
Rare Side-EffectsDACLIZUMAB : Frightening Thoughts, Bloody Or Red Colored Stools
Disease InteractionsDACLIZUMAB can interfere with: Depression, Bacterial Infection, Fungal Infection, Acute Liver Failure, Tuberculosis, Psoriasis, Eczema
Technical ClassificationDACLIZUMAB is categorized as: SELECTIVE IMMUNOSUPPRESSANTS / IMMUNOSUPPRESSIVE AGENTS / IMMUNOLOGIC AGENTS
What are the commonly available Substitutes?
|ZENAPAX 25MG INJ
|INR 23920 for 5 ML INJECTION
|DACLIZUMAB 25.0 MG